Data regarding the optimal approach for second allogeneic hematopoietic stem cell transplantation (HSCT) after graft failure (GF) in acquired severe aplastic anemia (SAA) are still limited and heterogeneous. We examined 24 patients who underwent second HLA-matched sibling donor (MSD) peripheral blood HSCT for GF. The reconditioning regimen (TNI-750/ATG) consisted of a single dose of total nodal irradiation (TNI, 750 cGy) and antithymocyte globulin (ATG; Thymoglobulin ® , 1.25 mg/kg/day for 3 days). All but one patient achieved successful engraftment of neutrophils (median 12 days, range 5-21) and platelets (median 15 days, range 9-316). Two patients with subsequent secondary GF achieved successful engraftment after a third HSCT from the same MSD. After a median follow-up of 57.4 months (range, 11.2-155.2), the 5-year overall survival and failure-free survival were 95.7% (95% confidence interval [CI] 87.7-100%) and 87.5% (95% CI 75.2-100%), respectively. One patient developed grade II acute graft-versus-host disease (GVHD), and the 2-year cumulative incidence of chronic GVHD was 23.5% (95% CI 8.1-43.5%). This study demonstrated successful outcomes following a second MSD HSCT in SAA after GF, and the results suggest TNI-750/ATG is a feasible reconditioning option. Future studies with larger cohorts will validate our results.
Introduction
Despite significant improvements in survival after allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-matched related and unrelated donors in acquired severe aplastic anemia (SAA), the development of severe graft dysfunction still remains a major concern [1, 2] . The rate of graft failure (GF) in SAA has decreased due to a strategy of earlier HSCT, which avoids heavy transfusion burdens, improved transplant-related procedures and transfusion practices, and the introduction of more immunosuppressive conditioning regimens such as a combination of fludarabine, cyclophosphamide, and antithymocyte globulin (ATG) [1, 3, 4] . However, despite the implementation of the previous mentioned strategies,~10% of patients still experience GF after HSCT [5] . Risk factors for graft rejection include multiple transfusions, low stem cell doses, T-cell depleted grafts, post-transplant complications such as cytomegalovirus (CMV), mycobacterial or fungal infections, acute and chronic graft-versus-host disease (GVHD), and various drugs [6] .
In cases with labile graft with mixed chimerism, interventions such as the use of growth factors [7] , alterations in immunosuppressive medication [8] , and/or CD34 + cells boost [9] can be attempted until it is determined that transfusion independence is likely to be obtained. In contrast, a second HSCT is the only effective salvage option for patients in GF with the absence of donor chimerism, transfusion re-dependence, or life-threatening neutropenia [10] . However, reconditioning in second HSCTs can be a concern as most patients with SAA in GF suffer from accumulated tissue damage from previous heavy transfusions and conditioning regimens, which predisposes recipients to transplant-related toxicity such as veno-occlusive disease and severe mucositis [1, 11] . The optimal strategy regarding transplant procedures for second transplantation in patients with SAA after GF is currently not established due to a lack of prospective randomized trials, as well as the clinical and treatment heterogeneity in the available retrospective reports [10] . In this study, we included 24 consecutive adult patients with SAA who underwent a second matched sibling donor (MSD) transplantation for the rescue of GF after an initial MSD HSCT. All patients received the same conditioning regimen consisting of a single dose of 750 cGy total nodal irradiation (TNI) combined with ATG after unmanipulated peripheral blood stem cell (PBSC) infusion. The aim of the present study is to evaluate the efficacy and safety of this approach for a second HSCT in adult patients with SAA in GF.
Methods

Patients
All adult patients (>18 years) with acquired SAA who had received a MSD HSCT between January 1995 and December 2014 at the Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, Seoul, Korea (n = 281) were retrospectively reviewed. Among them, a total of 24 consecutive patients were identified at data cutoff (31 March 2017), including 6 patients in a previous report from our institution, [12] who underwent a second MSD transplant for GF during the same period. The selection criteria for second transplantation for patients experiencing primary or secondary graft failure included an age of ≤60 years, an ECOG performance status of ≤2, no major organ failure, the donor availability, and the patient preference. This study was approved by the Institutional Review Board of the Catholic University of Korea (KC15RISI0872), and was conducted in accordance with the Declaration of Helsinki.
Second transplant procedures
The conditioning regimen of second MSD HSCT for GF in patients with SAA consisted of TNI administered as a single dose of 750 cGy on day −4, followed by rabbit ATG (Thymoglobulin ® , Genzyme, Cambridge, MA) given at a dose of 1.25 mg/kg/day for 3 consecutive days (TNI-750/ ATG). The clinical target volume for TNI corresponded to all lymphatic stations (bilateral neck from level II, bilateral axillae, mediastinum, paraaortic, bilateral common iliac, external and internal iliac, inguinal lymph nodes), and splenic hilum. Radiation was administered from a 6-MV linear accelerator (photon beam) targeted through the anterior and posterior portals. The non-lymphoid tissue was appropriately shielded from radiation for all fields. G-CSFmobilized PBSCs were infused on day 0. For GVHD prophylaxis, cyclosporine (5 mg/kg IV at day −1, then 3 mg/kg IV from day 0) with dose-adjustments targeting a trough level of 200-250 ng/mL plus short-course methotrexate (10 mg/m 2 IV at day +1, +3, +6, and +11) were administered. For supportive care, G-CSF (5 μg/kg/day) was administered to all patients from day +7 after the graft infusion until neutrophil recovery to 3 × 10 9 /L. Immunoglobulin (IVIg, Green Cross Corp, Korea; 500 mg/kg) was administered intravenously biweekly from day +7 to 3 months post-HSCT, followed by monthly administration until 9 months post-transplant. All patients received prophylactic ciprofloxacin antibiotic (1000 mg by mouth), antifungal agent itraconazole solution (400 mg by mouth), and antiviral agent acyclovir (800 mg by mouth). For prophylaxis of veno-occlusive disease, a low dose of heparin (Heparin sodium, Hanlim, Korea; 100 U/kg/day) or lipoprostaglandin E1 (Eglandin; alprostadil, Welfide, Osaka, Japan; 1 μg/kg/day) was continuously infused with ursodiol (200 mg thrice a day). The strategy for other general supportive care in our institution has previously been described [4, 13] .
Definitions of outcome assessment
The time to neutrophil engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count >0.5 × 10 9 /L. The time to platelet engraftment was defined as the first of 7 consecutive days with a platelet count >20 × 10 9 /L without transfusion support. Before the year 2002, donor chimerism was assessed using fluorescent in situ hybridization in sex-mismatched donor-recipient pairs. In sex-matched pairs, restriction fragment length polymorphism analysis using polymerase chain reaction (PCR) primers flanking the repeat units of human microsatellite markers was used, as the previously published method [14] . From 2002 onward, donor chimerism was assessed using PCR-based analysis of selected polymorphic short tandem repeats loci. Primary GF was considered as failure to achieve neutrophil engraftment by 28 days post-HSCT. Secondary GF was defined as an initial engraftment with documented donor-derived hematopoiesis followed by recurrent pancytopenia, with a markedly hypocellular bone marrow and blood transfusion dependency in the absence of acute GVHD [6] . GVHD was diagnosed and graded according to the clinical consensus criteria [15, 16] . The hematopoietic cell transplantation-comorbidity index was assessed based on the previously published criteria [17] . 
Statistical analyses
Treatment failure was defined as any cause of death and GF. Overall survival (OS) and failure-free survival (FFS) were assessed from the infusion day of the second HSCT to the time of event, using the Kaplan-Meier method. The engraftment and GVHD were estimated by the cumulative incidence methods. The cumulative incidence analyses were performed using the R software package (http://cran.rproject.org/). All other statistical analyses were performed using SPSS software (version 13.0; SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
The median patient age at the first and second transplant was 28 years (range, 18-47) and 33 years (range, 18-56), respectively ( Table 1 ). The stem cell source for the first MSD HSCT was bone marrow (BM), with the exception of 1 patient who received BM stem cells following CD34
+ enriched peripheral blood due to prior heavy transfusions (patient #4; Table 1 ), as previously described [18] . For the second transplant, all patients received G-CSF-mobilized PBSCs as a graft source without manipulation, except for 1 patient who received BM stem cells following CD34 + -purified peripheral blood (patient #10; Table 1 ). The type of graft failure was primary GF in 2 patients and secondary GF in 22 patients. The median interval between the first and the second transplant was 12.7 months (range, 1.0-159.6). The median number of red blood cell units transfused before the second HSCT was 43 units (range, 8-172), and median platelet units transfused was 57 units (range, . All patients underwent a second HSCT from the same MSD, with the exception of the 2 patients who received transplants from another MSD (patients #9 and #18). Further details on clinical characteristics are presented in Table 1 .
Engraftment and graft failure
The median number of infused CD34 + cells for the second transplant was 5.1 × 10 6 /kg (range, 1.6-14.4; Table 1 ). After the second transplant, neutrophil, and platelet engraftments were achieved in 23 of the 24 patients, at a median of 12 days (range, 5-21) and 15 days (range, 9-316), respectively (Fig. 1) . Details of hematologic recovery and donor chimerism are summarized in Table 2 . Primary GF after the second transplant occurred in one patient (patient #18). Nine months after the second transplant, this patient underwent a third transplant from another MSD using a conditioning regimen consisting of total body irradiation (TBI) at 800 cGy fractionated for 2 days, fludarabine 30 mg/ m 2 /day for 5 days, and ATG 2.5 mg/kg/day for 4 days, which failed again to engraft. Secondary GF occurred in two patients who had achieved an initial engraftment (patients #11 and #21). These two patients received the third HSCT following TBI (800 cGy fractionated in 2 days) and cyclophosphamide (60 mg/kg/day for 2 days) from the same MSD. Both patients achieved a successful neutrophil engraftment at 17 and 16 days post-HSCT, respectively, with complete donor chimerism. Donor-type aplasia occurred in one patient (#5) who showed a recurrent pancytopenia with 98% donorchimerism. This patient received a booster of PBSC at 15 months after the second HSCT and remained alive with stable graft function without GVHD.
GVHD and other complications
Acute GVHD grades II-IV developed in one patient: overall grade II 14 days after the second transplant, whereas chronic GVHD was observed in 6 patients (mild, n = 3; moderate, n = 3) with 1-year and 2-year cumulative incidences of 8.7% (95% confidence interval [CI] 1.4-24.6%) and 23.5% (95% CI 8.1-43.5%), respectively. All cases were successfully managed by glucocorticoid therapy with complete response. All surviving patients (n = 23) were off cyclosporine and/or steroids at their last follow-up.
In terms of early events by +100 days after the second transplantation, we observed two patients with varicella zoster virus infection (herpes zoster at +day 50 in patient #5; chicken pox at +day 30 in patient #23) and one patient with bacteremia caused by Corynebacterium spp. (+day 80 in patient #21). Patient#21 also developed tubo-ovarian abscess and fungal pneumonia (probable invasive pulmonary aspergillosis) at +170 days. CMV reactivation related to the second transplantation did not occur in this cohort. We observed neither pneumonitis nor sinusoidal obstruction syndrome.
Among late nonmalignant complications developed after second transplantation, osteonecrosis was diagnosed in two patients (+day 421 in patient#1; day 864 in patient#19), overt hypothyroidism in one (patient#19), osteoporosis in one (patient#15), and gonadal failure in one patient (patient#14). We did not observe other complications such as diabetes, cataract, or malignancy in this study until last follow-up.
Survivals
With a median follow-up of 57.4 months (range, 11.2-155.2) after the second HSCT, 23 of 24 patients remained alive ( Table 2 ). The 5-year OS (Fig. 2) and FFS of all patients were 95.7% (95% CI 87.7-100%) and 87.5% (95% CI 75.2-100%), respectively. One death (patient #18) occurred from a primary GF after the second and the subsequent third HSCT. None of the patients developed secondary malignancy after second HSCT at the last follow-up.
Discussion
The purpose of the conditioning regimen for patients with SAA is to suppress the recipient's immunity and prevent an immunological rejection of the donor grafts. We have employed a radiation-based conditioning with TNI and unmanipulated PBSC as a graft source to overcome the barriers of graft failure related to insufficient immunosuppression, inadequate numbers of transplanted stem cells, and a poor marrow microenvironment [10, 18] . The current study demonstrates that a single dose of 750 cGy TNI combined with ATG is a feasible conditioning regimen before a second MSD grafting for adult patients, with SAA in graft failure after a first MSD transplant. Although a small number of patients were included in this study, the results showed that the conditioning regimen was associated with minimal toxicity and long-term transfusion-free survival without clinically significant GVHD despite the number of prior transfusions, as well as the long disease duration by the time of the second transplantation.
Data on the transplant outcome as well as the optimal approach for patients undergoing a second transplantation for SAA are scarce and heterogeneous. A recent study from the European Society for Blood and Marrow Transplantation (EBMT) reported a 5-year OS of 62.4% for a second sibling HSCT in 110 patients with SAA in graft failure [19] . Another study using data from the Center for International Blood and Marrow Transplant Research (CIBMTR) showed that an intertransplantation interval of >3 months and a good Karnofsky performance score (90-100) at second transplantation from the same MSD in almost 90% of the cases were associated with better survival outcomes in SAA [20] . However, the authors were not able to identify an optimal conditioning regimen for a sustained hematopoietic recovery without a significant toxicity in the setting of a second HSCT in SAA due to heterogeneous conditioning regimens.
When cyclophosphamide alone was used as the preparative agent in heavily transfused patients, the graft failure rate was as high as 15-30% according to reported data [6] . Efforts to reduce graft failure included use of high-dose cyclophosphamide combining with TNI, and this resulted in a low rate of graft rejection in patients with SAA [21] . In a recent study by Muller et al., they demonstrated that donor cell engraftment first occurs in areas exposed to TNI and gradually redistributes to unexposed sites throughout the body. Although TNI/ATG-treated hosts were highly lympho-depleted, they suggested that the abilities of the donor cell redistribution and long-term engraftment come from the host regulatory T cells that are maintained following TNI/ ATG conditioning [22] .
The correlation between TNI dose and the efficacy of immunosuppression in SAA has been analyzed in previous studies [21] . According to a previous analysis of SAA patients undergoing a first transplantation, among 33 patients with MSD transplant using cyclophosphamide (50 mg/kg/day administered intravenously for 4 days) and 750 cGy TNI (1 day prior to HSCT), graft failure occurred in only one patient (3.0%), with a 7-year OS of 82% [23] . Alternatively, recent data using TNI (10 fractions of 0.8 Gy from 11 to 1 day prior to HSCT) and ATG conditioning regimen (1.5 mg/kg per day starting from 11 days prior to HSCT for 5 consecutive days) from a Stanford group examining 111 patients with hematologic malignancies undergoing HLA-matched HSCT. They showed 96% of multilineage donor HSC engraftments with a 1-year cumulative risk of treatment-related mortality of 3% and 4% for related and unrelated donor transplants, respectively [24] . While evidence shows the exponential depletion of peripheral blood lymphocytes as a function of TNI dose, clinical trials using TNI with cyclophosphamide have demonstrated that 600 to 750 cGy is an effective immunosuppressive regimen for sensitized SAA patients [21] . Another important factor associated with graft rejection after allogeneic HSCT in SAA is the CD34 + cell count infused [10] . Patients in our study received mobilized PBSCs in an attempt to assure an adequate number of stem cells will be infused. In the current study, 23 of 24 patients (96%) achieved primary engraftment with a median time of 12 days (range, 5-21) after a second transplant, which compares favorably with data from EBMT [19] and CIBMTR [20] . Although 2 of the 23 patients subsequently experienced a delayed graft failure, both of the patients underwent a successful third HSCT using 800 cGy TBI in combination with cyclophosphamide (120 mg/kg), and continued to survive with normal blood counts without any immunosuppressant.
There are several important limitations in our study that preclude drawing definitive conclusions about the favorable outcome of our data: the retrospective and descriptive design and the small sample size of this study limited our ability to adequately exclude confounding variables and selection bias. Any statistical analysis is therefore difficult to interpret due to low power.
In conclusion, our data demonstrates the feasibility of using TNI and ATG as reconditioning for a second HSCT in SAA after graft failure. With this conditioning regimen, a low incidence of problematic GVHD is expected, even when using PBSC as a graft source. Although this study has the inherent limitations of a retrospective analysis and a small sample size, the results support the need for future study in a larger group of SAA patients to verify the suggested benefits of this conditioning regimen for a second HSCT in graft failure. Fig. 2 The overall survival after the second MSD HSCT in adult patients with SAA in graft failure
